Sanofi Gets Approval For SU-type Amaryl ODTs
This article was originally published in PharmAsia News
Sanofi announced Aug. 16 it received approval for sulphonylurea oral hypoglycemic agent Amaryl (glimepiride) for Type II diabetes in 0.5mg orally disintegrating tablets.
You may also be interested in...
Recent updates to FDA recalls database also include single lots of three package sizes of Johnson’s Baby Powder after testing found sub-trace levels of chrysotile asbestos contamination and 5,720 bottles of homeopathic OTCs made in India for West Virginia firm Washington Homeopathic Products Inc. at a facility noncompliant with the agency’s good manufacturing practices regulations.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?